Home
Click
Emmet Mc Cormack's picture

Emmet Mc Cormack

Professor, Pharmaceutics and Pharmaceutical Technology
  • E-mailEmmet.Mc.Cormack@uib.no
  • Phone+47 55 97 46 28
  • Visitor Address
    9th Floor Lab building, Haukeland University Hospital
    Bergen
  • Postal Address
    Postboks 7804
    5020 Bergen

Preclinical model development

Preclinical multimodal imaging

Pharmaceutical drug development

BMED 320: Methods in Medical Cell Biology

FARM 295: Pharmaceutics

Dimcevski G, Kotopoulis S, Bjånes T, Hoem D, Schjøt J, Gjertsen BT, Biermann M, Molven A, Sorbye H, McCormack E, Postema M, Gilja OH. A human clinical trial using ultrasound and microbubbles to enhance gemcitabine treatment of inoperable pancreatic cancer. J Control Release. 2016 Oct 12. pii: S0168-3659(16)30949-X. doi: 10.1016/j.jconrel.2016.10.007. PubMed PMID: 27744037.

5 year Impact Factor: 8.41

 

Bojan A, Berindan-Neagoe I, Ciurea S, Dima D, Fuji S, Ghiaur G, Grewal R, Mccormack E, Tanase A, Trifa A, Tomuleasa C. Proceedings from the 1st Insights in Hematology Symposium, Cluj-Napoca, Romania March 11-12, 2016. Rom J Intern Med. 2016 Sep 1;54(3):157-160.

 

Helland Ø, Popa M, Bischof K, Gjertsen BT, McCormack E, Bjørge L. The HDACi Panobinostat Shows Growth Inhibition Both In Vitro and in a Bioluminescent Orthotopic Surgical Xenograft Model of Ovarian Cancer. PLoS One. 2016 Jun 28;11(6):e0158208.         Impact Factor (IF): 3.23

 

Suliman S, Mustafa K, Krueger A, Steinmüller-Nethl D, Finne-Wistrand A, Osdal T, Hamza AO, Sun Y, Parajuli H, Waag T, Nicke J, Johannessen AC, McCormack E, Costea DE. Nanodiamond modified copolymer scaffolds affects tumour progression of early neoplastic oral keratinocytes. Biomaterials. 2016 Apr 6.        doi:10.1016/j.biomaterials.2016.04.002 [Epub ahead of print] 5 year Impact Factor: 9.31

 

Mamaeva V, Niemi R, Beck M, Özliseli E, Desai D, Landor S, Gronroos T, Kronqvist P, Pettersen IK, McCormack E, Rosenholm JM, Linden M, Sahlgren C. Inhibiting Notch activity in breast cancer stem cells by glucose functionalized nanoparticles carrying γ- secretase inhibitors. Mol Ther. 2016 Feb 26. doi: 10.1038/mt.2016.42. [Epub ahead of print]  IF: 6.83

 

Leitch C, Osdal T, Andresen V, Molland M, Kristiansen S, Nguyen XN, Bruserud Ø, Gjertsen BT, McCormack E. Hydroxyurea synergizes with valproic acid in wild-type p53 acute myeloid leukaemia. Oncotarget. 2016 Jan 23. doi: 10.18632/oncotarget.6991. [Epub ahead of print] IF: 6.38

 

Gelebart P, Popa M, McCormack E. Xenograft Models of Primary Acute Myeloid Leukemia for the Development of Imaging Strategies and Evaluation of Novel Targeted Therapies. Curr Pharm Biotechnol. 2016;17(1):42-51.        IF: 2.51

 

Suliman S, Parajuli H, Sun Y, Johannessen AC, Finne-Wistrand A, McCormack E, Mustafa K, Costea DE. Establishment of a bioluminescence model for microenvironmentally induced oral carcinogenesis with implications for screening bioengineered scaffolds. Head Neck. 2015 Aug 14. doi: 10.1002/hed.24187. [Epub ahead of print]                 IF: 2.64

 

Haldorsen IS, Popa M, Fonnes T, Brekke N, Kopperud R, Visser NC, Rygh CB, Pavlin T, Salvesen HB, McCormack E, Krakstad C. Multimodal Imaging of Orthotopic Mouse Model of Endometrial Carcinoma. PLoS One. 2015 Aug 7;10(8):e0135220.            IF: 3.23

 

Vorobyeva AG, Stanton M, Godinat A, Lund KB, Karateev GG, Francis KP, Allen E, Gelovani JG, McCormack E, Tangney M, Dubikovskaya EA. Development of a Bioluminescent Nitroreductase Probe for Preclinical Imaging. PLoS One. 2015 Jun 25;10(6):e0131037.           IF: 3.23

 

Hampson P, Wang K, Ersvær E, McCormack E, Schüler J, Fiebig HH, Gjertsen BT, Bruserud Ø, Lord JM. Up-regulation of anti-apoptotic genes confers resistance to  the novel anti-leukaemic compound PEP005 in primary AML cells. Oncoscience. 2014  Aug 6;1(8):529-39.

 

Li L, Osdal T, Ho Y, Chun S, McDonald T, Agarwal P, Lin A, Chu S, Qi J, Li L,  Hsieh YT, Dos Santos C, Yuan H, Ha TQ, Popa M, Hovland R, Bruserud O, Gjertsen BT, Kuo YH, Chen W, Lain S, McCormack E*, Bhatia R*. SIRT1 activation by a c-MYC oncogenic network promotes the maintenance and drug resistance of human FLT3-ITD  acute myeloid leukemia stem cells. Cell Stem Cell. 2014 Oct 2;15(4):431-46. *Joint correspondence            IF: 25.56

 

- This article was highlighted with commentary in Cell Stem Cell: Zeisig BB, So CW. A knockout Combo: eradicating AML Stem Cells with TKI plus SIRT1 inhibition. Cell Stem Cell. 2014 Oct 2;15(4):395-7

 

 

 Haaland I, Opsahl JA, Berven FS, Reikvam H, Fredly HK, Haugse R, Thiede B, McCormack E, Lain S, Bruserud O, Gjertsen BT. Molecular mechanisms of nutlin-3 involve acetylation of p53, histones and heat shock proteins in acute myeloid leukemia. Mol Cancer. 2014 May 21;13:116. IF: 4.26

 

Helland O, Popa M, Vintermyr OK, Molven A, Gjertsen BT, Bjørge L, McCormack E. First in-mouse development and application of a surgically relevant xenograft  model of ovarian carcinoma. PLoS One. 2014 Mar 4;9(3):e89527. IF: 3.23

 

Poli A, Wang J, Domingues O, Planagumà J, Yan T, Rygh CB, Skaftnesmo KO, Thorsen F, McCormack E, Hentges F, Pedersen PH, Zimmer J, Enger PØ, Chekenya M. Targeting glioblastoma with NK cells and mAb against NG2/CSPG4 prolongs animal survival. Oncotarget. 2013 Sep;4(9):1527-46                     IF: 6.38

 

Qu Y, Oyan AM, Liu R, Hua Y, Zhang J, Hovland R, Popa M, Liu X, Brokstad KA, Simon R, Molven A, Lin B, Zhang WD, McCormack E, Kalland KH, Ke XS. Generation of prostate tumor-initiating cells is associated with elevation of reactive oxygen species and IL-6/STAT3 signaling. Cancer Res. 2013 Dec 1;73(23):7090-100.                      IF: 9.33

 

Kotopoulis S, Delalande A, Popa M, Mamaeva V, Dimcevski G, Gilja OH, Postema  M, Gjertsen BT, McCormack E. Sonoporation-enhanced chemotherapy significantly reduces primary tumour burden in an orthotopic pancreatic cancer xenograft. Mol Imaging Biol. 2014 Feb;16(1):53-62.      IF: 2.47

 

Jarzabek MA, Huszthy PC, Skaftnesmo KO, McCormack E, Dicker P, Prehn JH, Bjerkvig R, Byrne AT. In vivo bioluminescence imaging validation of a human biopsy-derived orthotopic mouse model of glioblastoma multiforme. Mol Imaging. 2013 May;12(3):161-72.        IF: 1.96

 

Gausdal G, Wergeland A, Skavland J, Nguyen E, Pendino F, Rouhee N, McCormack  E, Herfindal L, Kleppe R, Havemann U, Schwede F, Bruserud O, Gjertsen BT, Lanotte M, Ségal-Bendirdjian E, Døskeland SO. Cyclic AMP can promote APL progression and  protect myeloid leukemia cells against anthracycline-induced apoptosis. Cell Death Dis. 2013 Feb 28;4:e516.        IF: 5.01

 

Silden E, Hjelle SM, Wergeland L, Sulen A, Andresen V, Bourdon JC, Micklem DR, McCormack E, Gjertsen BT. Expression of TP53 isoforms p53β or p53γ enhances chemosensitivity in TP53(null) cell lines. PLoS One. 2013;8(2):e56276. IF: 3.23

 

Qu Y, Li WC, Hellem MR, Rostad K, Popa M, McCormack E, Oyan AM, Kalland KH, Ke XS. MiR-182 and miR-203 induce mesenchymal to epithelial transition and self-sufficiency of growth signals via repressing SNAI2 in prostate cells. Int J  Cancer. 2013 Aug 1;133(3):544-55.          IF: 5.09

 

McCormack E, Adams KJ, Hassan NJ, Kotian A, Lissin NM, Sami M, Mujić M, Osdal T, Gjertsen BT, Baker D, Powlesland AS, Aleksic M, Vuidepot A, Morteau O, Sutton  DH, June CH, Kalos M, Ashfield R, Jakobsen BK. Bi-specific TCR-anti CD3 redirected T-cell targeting of NY-ESO-1- and LAGE-1-positive tumors. Cancer Immunol Immunother. 2013 Apr;62(4):773-85.  IF: 3.94

Figures from this article made the front cover of the Journals April edition 2013

 

McCormack E, Mujić M, Osdal T, Bruserud Ø, Gjertsen BT. Multiplexed mAbs: a new strategy in preclinical time-domain imaging of acute myeloid leukemia. Blood. 2013 Feb 14;121(7):e34-42.            IF: 11.84

 

McCormack E, Silden E, West RM, Pavlin T, Micklem DR, Lorens JB, Haug BE, Cooper ME, Gjertsen BT. Nitroreductase, a near-infrared reporter platform for in vivo time-domain optical imaging of metastatic cancer. Cancer Res. 2013 Feb 15;73(4):1276-86.   IF: 9.33

 

Forthun RB, Sengupta T, Skjeldam HK, Lindvall JM, McCormack E, Gjertsen BT, Nilsen H. Cross-species functional genomic analysis identifies resistance genes of the histone deacetylase inhibitor valproic acid. PLoS One. 2012;7(11):e48992 IF: 3.23

 

Lee J, Li M, Milwid J, Dunham J, Vinegoni C, Gorbatov R, Iwamoto Y, Wang F, Shen K, Hatfield K, Enger M, Shafiee S, McCormack E, Ebert BL, Weissleder R, Yarmush ML, Parekkadan B. Implantable microenvironments to attract hematopoietic  stem/cancer cells. Proc Natl Acad Sci U S A. 2012 Nov 27;109(48):19638-43. IF: 9.67

- This article was highlighted with commentary in Nature Methods: de Souza N.Stem cells: Blood matters. 2013 Jan;10(1):9.

 

Hjelle SM, Sulen A, Øye OK, Jørgensen K, McCormack E, Hollund BE, Gjertsen BT. Leukocyte p53 protein biosignature through standard-aligned two-dimensional immunoblotting. J Proteomics. 2012 Dec 5;76 Spec No.:69-78.            IF: 3.81

 

Karlsen TV, McCormack E, Mujic M, Tenstad O, Wiig H. Minimally invasive quantification of lymph flow in mice and rats by imaging depot clearance of near-infrared albumin. Am J Physiol Heart Circ Physiol. 2012 Jan;302(2):H391-401 IF: 3.84

 

McCormack E, Haaland I, Venås G, Forthun RB, Huseby S, Gausdal G, Knappskog S, Micklem DR, Lorens JB, Bruserud O, Gjertsen BT. Synergistic induction of p53 mediated apoptosis by valproic acid and nutlin-3 in acute myeloid leukemia. Leukemia. 2012 May;26(5):910-7.          IF: 12.10

 

Ke XS, Li WC, Hovland R, Qu Y, Liu RH, McCormack E, Thorsen F, Olsen JR, Molven A, Kogan-Sakin I, Rotter V, Akslen LA, Oyan AM, Kalland KH. Reprogramming  of cell junction modules during stepwise epithelial to mesenchymal transition and accumulation of malignant features in vitro in a prostate cell model. Exp Cell Res. 2011 Jan 15;317(2):234-47.         IF: 3.25

 

Wang J, Daphu I, Pedersen PH, Miletic H, Hovland R, Mørk S, Bjerkvig R, Tiron C, McCormack E, Micklem D, Lorens JB, Immervoll H, Thorsen F. A novel brain metastases model developed in immunodeficient rats closely mimics the growth of metastatic brain tumours in patients. Neuropathol Appl Neurobiol. 2011 Feb;37(2):189-205.  IF: 3.93

 

Torsvik A, Røsland GV, Svendsen A, Molven A, Immervoll H, McCormack E, Lønning PE, Primon M, Sobala E, Tonn JC, Goldbrunner R, Schichor C, Mysliwietz J, Lah TT, Motaln H, Knappskog S, Bjerkvig R. Spontaneous malignant transformation of human mesenchymal stem cells reflects cross-contamination: putting the research field on track - letter. Cancer Res. 2010 Aug 1;70(15):6393-6.  IF: 9.33

 

McCormack E, Skavland J, Mujic M, Bruserud Ø, Gjertsen BT. Lentinan: hematopoietic, immunological, and efficacy studies in a syngeneic model of acute  myeloid leukemia. Nutr Cancer. 2010;62(5):574-83.               IF: 2.32

 

Gjerdrum C, Tiron C, Høiby T, Stefansson I, Haugen H, Sandal T, Collett K, Li S, McCormack E, Gjertsen BT, Micklem DR, Akslen LA, Glackin C, Lorens JB. Axl is  an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival. Proc Natl Acad Sci U S A. 2010 Jan 19;107(3):1124-9.        IF: 9.67

 

- This article was highlighted with commentary in the Nature publications SciBX and Nature Biotechnology:

Lou KJ. Breaking the code for Axl in metastasis. SciBX 2010 3(4); doi:10.1038/scibx.2010.106

Sheridan C. First Axl inhibitor enters clinical Trial. Nat. Biotechnol. 2013 Sep;31(9):775-6.

 

Erikstein BS, McCormack E, Tronstad KJ, Schwede F, Berge R, Gjertsen BT. Protein kinase A activators and the pan-PPAR agonist tetradecylthioacetic acid elicit synergistic anti-leukaemic effects in AML through CREB. Leuk Res. 2010 Jan;34(1):77-84.      IF: 2.35

 

Hofmann M, McCormack E, Mujić M, Rossberg M, Bernd A, Bereiter-Hahn J, Gjertsen BT, Wiig H, Kippenberger S. Increased plasma colloid osmotic pressure facilitates the uptake of therapeutic macromolecules in a xenograft tumor model.  Neoplasia. 2009 Aug;11(8):812-22.   IF: 4.25

 

Røsland GV, Svendsen A, Torsvik A, Sobala E, McCormack E, Immervoll H, Mysliwietz J, Tonn JC, Goldbrunner R, Lønning PE, Bjerkvig R, Schichor C. Long-term cultures of bone marrow-derived human mesenchymal stem cells frequently undergo spontaneous malignant transformation. Cancer Res. 2009 Jul 1;69(13):5331-9.   IF: 9.33

 

McCormack E, Bruserud O, Gjertsen BT. Review: genetic models of acute myeloid leukaemia. Oncogene. 2008 Jun 19;27(27):3765-79.           IF: 8.46

 

Gausdal G, Gjertsen BT, McCormack E, Van Damme P, Hovland R, Krakstad C, Bruserud Ø, Gevaert K, Vandekerckhove J, Døskeland SO. Abolition of stress-induced protein synthesis sensitizes leukemia cells to anthracycline-induced death. Blood. 2008 Mar 1;111(5):2866-77.   IF: 11.84

 

Ersvaer E, Zhang JY, McCormack E, Olsnes A, Anensen N, Tan EM, Gjertsen BT, Bruserud O. Cyclin B1 is commonly expressed in the cytoplasm of primary human acute myelogenous leukemia cells and serves as a leukemia-associated antigen associated with autoantibody response in a subset of patients. Eur J Haematol. 2007 Sep;79(3):210-25.       IF: 2.07

 

McCormack E, Micklem DR, Pindard LE, Silden E, Gallant P, Belenkov A, Lorens  JB, Gjertsen BT. In vivo optical imaging of acute myeloid leukemia by green fluorescent protein: time-domain autofluorescence decoupling, fluorophore quantification, and localization. Mol Imaging. 2007 May-Jun;6(3):193-204.     IF: 1.96

 

McCormack E, Bruserud O, Gjertsen BT. Animal models of acute myelogenous leukaemia - development, application and future perspectives. Leukemia. 2005 May;19(5):687-706.      IF: 12.10

 

Gjertsen BT, Mc Cormack E. Erythropoietin a safe bet in haemorrhagic shock? Acta Anaesthesiol Scand. 2008 May;52(5):585-6.        IF: 2.36

 

 

Sjøholt G, Anensen N, Wergeland L, Mc Cormack E, Bruserud Ø, Gjertsen BT. Proteomics in acute myelogenous leukaemia (AML): methodological strategies and identification of protein targets for novel antileukaemic therapy. Curr Drug Targets. 2005 Sep;6(6):631-46.           IF: 3.26

 

 

PATENTS

John Jarlath WALSH, Richard Shah, Emmet Martin MCCORMACK, Gillian Joy HUDSON, Martina WHITE, Gary Daniel STACK, Brian William MORAN, Adrian COOGAN, Elaine Carmel BREEN. Tubulin Binding Agents. WO2013026942 A1

 

 

BOOKS

Haslene-Hox, H., Silden, E.,Mujic, M., Matre, K., McCormack, E. (2011) 2011 Joint National Ph.D. Conference in Medical Imaging and MedViz Conference.

ISBN: 978-82-993786-6-6

 

Mc Cormack, E. M. (2002). Design, synthesis and in vitro evaluation of novel anti-cancer compounds. Ph.D Thesis, Trinity College Dublin, Dublin, Ireland.

 

 

POPULAR SCIENTIFIC CONTRIBUTIONS

Holthe, K. (2016, April 4). Denne musa får menneskekreft for at du skal få bedre behandling. Tv2. Retrieved from http://www.tv2.no/a/8141256/

 

McCormack, E. (2014, October 13). Egne stamceller kan gi din helt unike kreftmedisin. Aftenposten. Retrieved from http://www.aftenposten.no/viten/Egne-stamceller-kan-gi-din-helt-unike-kr...

 

Hågøy, T. (2013, April 15). Kan revolusjonere kreftbehandlingen. Dagens Medisin.

Retrieved from http://www.dagensmedisin.no/artikler/2013/04/15/kan-revolusjonere-kreftbehandlingen/

 

Bakke, K. A. (2011, December 16). Nye muligheter for kreftprotein. Dagens Medisin. Retrieved from http://www.dagensmedisin.no/artikler/2011/12/16/nye-muligheter-for-kreft...

Publications in national current research information system (CRIStin)

B.Sc. Applied Sciences (Chemistry and Mathematics) - D.I.T/Trinity College Dublin

Ph.D Pharmacy - Trinity College Dublin

SonoCURE: Sonoporation-Enhanced Therapy for the treatment of Pancreatic Adenocarcinoma.

Funding: FRIPRO, Research Council of Norway

 

AML-VACCiN: Clinical development of a dendritic-cell vaccine therapy for acute myeloid leukaemia

Funding: H2020 program PHC-14-2015 - New therapies for rare diseases

Read more here

 

Re-development of Elacytarabine for Acute Myeloid Leukemia

Funding: Exploratory Pre Seed Grants, NOVO Nordisk Fonden

 

Personalized treatment in acute myeloid leukemia guided by targeted proteomics

Funding: Norwegian Cancer Society

 

Translational Development of Preclinical Models and Therapies in Myeloid Neoplasia

Funding: Norwegian Cancer Society

Read more here

 

ISPIC - Image-Guided Surgery and Personalised Postoperative Immunotherapy to Improving Cancer Outcome

Funding: H2020 program MSCA-ITN funded by the EC

Read more here